Gilead Sciences Inc. (NASDAQ:GILD) has announced it will be taking over HOOKIPA Pharma Inc. (NASDAQ:HOOK) for a consideration ...

HOOKIPA Pharma (HOOK) stock gains as Gilead Sciences agrees to acquire some of its antiviral assets for up to $10M. Read more ...

Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

Following the completion of the Phase 1b trial, Gilead will have the exclusive right to further develop the program.

Jan 15 (Reuters) - Gilead Sciences (GILD.O), opens new tab and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to ...

Poolbeg Pharma plc and HOOKIPA Pharma Inc. provided an update on their potential combination, noting Gilead Sciences Inc.'s intention to participate in a related fundraising effort with a ...

Further to the announcement on 2 January 2025 (the "2.4 Announcement"), the Boards of Poolbeg and HOOKIPA are pleased to confirm that significant HOOKIPA shareholder, Gilead Sciences Inc. ("Gilead"), ...

("HOOKIPA") and Poolbeg Pharma plc ("Poolbeg ... The Combined Group would also have two partnered programmes with Gilead Sciences, Inc. ("Gilead"), offering the potential of significant ...

Gilead ”), offering the potential of significant ... for the Combined Group's shareholders. HOOKIPA is listed on the Nasdaq Capital Market under the symbol HOOK and Poolbeg is listed on AIM ...